Last reviewed · How we verify
NCT05038618
A Study o Evaluate the Safety, Tolerability, and Immunogenicity of MVC-COV1901, CT-COV-21 Sub-study
Phase 2 trial testing MVC-COV1901(S protein with adjuvant) in Covid19 Vaccine in 399 participants. Completed in 11 March 2022.
14 October 2021
Quick facts
| Lead sponsor | Medigen Vaccine Biologics Corp. |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 399 |
| Start date | 2 August 2021 |
| Primary completion | 14 October 2021 |
| Estimated completion | 11 March 2022 |
| Sites | 1 location across Taiwan |
Drugs / interventions tested
- MVC-COV1901(S protein with adjuvant) — full drug profile →
Conditions studied
- Covid19 Vaccine — all drugs for Covid19 Vaccine →
Sponsor
Medigen Vaccine Biologics Corp. — full company profile →
Who can join
Adults 20 to 64, any sex, with Covid19 Vaccine. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This sub-study is a prospective open-label, single-center study to demonstrate comparability of different manufacturing scales.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05038618
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of MVC-COV1901(S protein with adjuvant)
Trials testing the same drug.
- NCT04951388 — A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Adolescents · Phase 2 · completed
- NCT05048849 — A Study to Evaluate the Safety, Tolerability, and Immunogenicity of COVID-19 Vaccine, CT-COV-21 Extension Study · Phase 2 · completed
- NCT04695652 — A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Adult · Phase 2 · completed
Other Medigen Vaccine Biologics Corp. trials
Trials by the same sponsor.
- NCT07178522 — A Study to Evaluate the Immunogenicity and Safety of an EV71 Vaccine (Envacgen®) in Children Aged 6 to <10 Years Compare · Phase 3 · recruiting
- NCT05198596 — A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Compared With AZD1222 in Adults Aged 18 Years and Above · Phase 3 · completed
- NCT05426343 — A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Vaccine Compared With AZD1222 · Phase 3 · completed
- NCT05216601 — A Study to Evaluate the Safety, Tolerability, and Immunogenicity of MVC-COV1901 or MVC-COV1901(Beta) Against COVID-19 · Phase 1 · completed
- NCT05197153 — A Study to Evaluate the Safety and Immunogenicity of Booster With AZD1222, mRNA-1273, or MVC-COV1901 Against COVID-19 · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05038618 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Medigen Vaccine Biologics Corp.
- Last refreshed: 13 June 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05038618.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing